BOSTON & PERTH, Australia--(BUSINESS WIRE)--Sept. 13, 2006--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that a paper describing the initial clinical work on its lead ophthalmology product Retisert(TM), has been awarded first prize in the field of Clinical Uveitis by the DUAG (Deutsche Uveitis-Arbeitsgemeinschaft), the umbrella organization of all German uveitis patient interest groups.
